Introduction {#S1}
============

DCs are professional antigen-presenting cells (APCs) with key regulatory roles in maintaining tolerance to self-antigens and in activating innate and adaptive immunity^[@R1]^. These cells express abundant pattern-recognition receptors (PRR) to recognize conserved microbial structures such as lipopolysaccharide (LPS), unmethylated bacterial DNA (CpG), and RNA^[@R2]--[@R4]^ for activating NF-kB and other signaling pathways^[@R2]--[@R3]^. NF-kB activation promotes APCs to express higher levels of costimulatory molecules and proinflammatory cytokines, and to present MHC-restricted peptides to T cells for inducing both primary and secondary immune responses^[@R2]--[@R3]^. Regulation of NF-kB signaling is critical, not only for APCs to stimulate immune responses to viral and bacterial infections, but also to avoid inducing an immune response to self-tissue, including tumor tissue. There is now substantial evidence that DCs are equipped with key regulatory mechanisms to attenuate NF-kB signaling and prevent their differentiation to APCs for maintaining self-tolerance^[@R5]--[@R6]^.

A20, a zinc finger ubiquitin-modifying enzyme, is defined as a negative regulator of NF-kB signaling^[@R7]--[@R10]^. A20 inhibits several key upstream signal transduction pathways of NF-kB induced by Toll-like receptor (TLR), the tumor necrosis factor receptor (TNFR), and retinoic acid-inducible gene I (RIG-I) in a feedback manner^[@R7]--[@R11]^ by ubiquitination or deubiquitination of receptor interacting protein (RIP), TNFR-associated factor (TRAF) 6, and other molecules for either promoting target protein degradation or regulating interaction of the target proteins with other signaling molecules^[@R7]--[@R11]^. Because TRAF6 is a common signaling component that is shared by all the members of the NF-kB family, A20 suppresses both MyD88-dependent and MyD88-independent NF-kB-signaling pathways. A20-deficient mice develop severe inflammation in multiple organs, are neonatally lethal, and highly hypersensitive to LPS and TNF^[@R7]--[@R8],\ [@R10]^. A20-deficient Mфs exhibit prolonged NF-κB activity^[@R7],\ [@R10]^. Our recent study further explored that A20 negatively regulates the maturation, inflammatory cytokine production, and immunostimulatory potency of DCs^[@R6]^. These results indicate an essential role of A20 in the maintenance of self-tolerance by regulating inflammatory signaling.

EBV, a human γ herpes virus with tropism for B cells, has been implicated in a variety of human tumorigenesis. In immunosuppressive patients, EBV-associated lymphoproliferative diseases express all of the EBV latent antigens^[@R12]^, which make CTL-based adoptive immunotherapy extremely effective in confining the diseases^[@R13]--[@R14]^. However, in immunocompetent hosts, EBV-associated malignancy only expresses subdominant EBV antigens, primarily, LMP1 and LMP2^[@R12],\ [@R15]--[@R16]^. Although LMP antigens are conserved between viral strains and among Hodgkin lymphoma biopsy samples^[@R17]--[@R19]^, these subdominant antigens have poor immunogenicity and possess oncogenic potential^[@R20]--[@R21]^. Furthermore, the precursor frequency of LMP-specific CTLs is generally low in healthy virus-carriers^[@R20],\ [@R22]^. Thus, generation of LMP-specific CTL for adoptive immunotherapy represents a big challenge. In the present study, we report that transitively expressing an A20 inhibitor together with LMP genes (truncated LMP1 and full-length LMP2) greatly enhances maturation and cytokine production of hDCs. Consequently, LMP1/2-expressing, A20-silenced hDCs have an enhanced potency to prime an LMP-specific T cell response. When the *in vitro* primed T cells are adoptively transferred into tumor-xenografted SCID mice, some of the xenografted tumors approach complete regression. Hence, the study may provide an available approach to generate LMP-specific CTLs for adoptive immunotherapy.

Results {#S2}
=======

Construction and characterization of pshA20-LMP1/2 {#S3}
--------------------------------------------------

Potential EBV antigen targets for T cell therapy are limited to the subdominant antigens such as LMP1 and LMP2 which are expressed by the malignant tumors^[@R23]--[@R25]^. However, LMP-pulsed or expressed DCs may not prime a potent CTL response, as DCs are built-in with an inherent negative regulation mechanism to limit their maturation and immunostimulatory activity for homeostasis and immune tolerance. A20, a zinc finger ubiquitin-modifying enzyme, was reported to negatively regulate DC maturation and cytokine production. A20 silencing greatly promoted DCs to induce anti-tumor immunity. Thus, we constructed a co-expression vector pshuttleX-A20shRNA-ΔLMP1/LPM2 (pshA20-LMP1/2), which expresses the A20 shRNA under the control of the U6 promoter and a LMP1 truncate/LMP2 under the control of CMV promoter based on the fact that a full-length LMP1 is toxic when expressed at high levels^[@R26]^. The control vector pshuttleX-ΔLMP1-LMP2 (pLMP1/2) only expresses the LMP1 truncate and LMP2 ([Fig. 1A](#F1){ref-type="fig"}). The recombinant vectors were transfected into hDCs by nucleofection which delivered a reporter vector pmaxGFP into hDCs with 92% efficiency ([Supplemental Fig. 1A](#SD2){ref-type="supplementary-material"}). Expression of the LMP1/2 in the pshA20-LMP1/2-transfected hDCs were confirmed by western blot at the protein level ([Fig. 1B](#F1){ref-type="fig"}) and by qPCR at the mRNA level ([Fig. 1C](#F1){ref-type="fig"}). Efficiency of pshA20-LMP1/2 transfecting hDCs, which is close to \~69%, was determined by ICS analysis of intracellular LMP1 expression ([Supplemental Fig. 1B](#SD2){ref-type="supplementary-material"}). To test if pshA20-LMP1/2 reduces A20 expression in the transfected hDCs, differently nucleofected or Mock hDCs were stimulated with LPS overnight, given that A20 is an inducible, feedback regulator of TLR and TNFR-mediated signaling^[@R6]--[@R7]^. qPCR assay explored that pshA20-LMP1/2 transfected hDCs express a drastically lower level of A20 mRNA in comparison with the control DCs ([Fig. 1D](#F1){ref-type="fig"}, **upper**). Western Blot further demonstrated that pshA20-LMP1/2 transfected hDCs expressed a reduced level of A20 protein ([Fig. 1D](#F1){ref-type="fig"}, **lower**). As LMP1 is known to induce A20 expression^[@R27]^, we also examined the A20 level in unstimulated, differently transfected hDCs by qPCR and western blot. We did not find that pLMP1/2-transfected hDCs expressed any enhanced level of A20 on both mRNA level and protein level ([Supplemental Fig. 2](#SD2){ref-type="supplementary-material"}), suggesting the truncated LMP1 does not maintain the function of the full-length LMP1. These results demonstrate pshA20-LMP1/2 transfected hDCs efficiently express the EBV subdominant antigens ΔLMP1 and LMP2, but inefficiently express the negative regulator A20 in response to LPS stimulation.

pshA20-LMP1/2 transfection enhances hDC maturation and cytokine production {#S4}
--------------------------------------------------------------------------

We next tested maturation status of pshA20-LMP1/2-nucleosfected DCs in response to LPS stimulation by examining expression of costimulatory and MHC molecules via flow cytometric analysis. As shown in [Fig. 2A](#F2){ref-type="fig"}, compared with pLMP1/2-transfected or Mock DCs, pshA20-LMP1/2-transfected DCs expressed significantly higher levels of CD80, CD86, MHC class-II molecule HLA-DR, and slightly higher levels of CD83 and chemokine receptor CCR7 at the single-cell level, although CD40 expression by differently transfected DCs or Mock DCs was very similar. Furthermore, we tested inflammatory cytokine production by differently transfected or Mock DCs. As shown in [Fig. 2B](#F2){ref-type="fig"}, pshA20-LMP1/2-transfected DCs produced significantly higher levels of IL-6, TNF-α, and IL-12 than the control DCs in response to LPS stimulation. We also found that pshA20-LMP1/2-transfected DCs produced a higher level of IL-10, which is consistent with our previous studies in mouse models^[@R28]--[@R29]^. The results suggest that pshA20-LMP1/2 transfection endows DCs with enhanced maturation and activation due to the silencing of the negative regulator A20.

pshA20-LMP1/2 transfection enhances stimulatory activity of hDCs in priming autologous CD8^+^ T cells *in vitro* {#S5}
----------------------------------------------------------------------------------------------------------------

To test if pshA20-LMP1/2 transfection enhances the stimulatory potency of hDCs in priming LMP-specific T cells, hDCs differentiated from HLA-A2^+^ healthy buffy coats were nucleofected with pshA20-LMP1/2, pLMP1/2, or Mock followed by LPS stimulation. Autologous human lymphocytes were cocultured with differently transfected or Mock DCs for 2--3 weeks to prime or activate LMP-specific CTLs. In cocultures with pshA20-LMP1/2-transfected DCs, 5.22% or 22.5% of CD8^+^ T cells were found positive for the LMP1 or LMP2-tetramer staining, compared with only 2.98% or 13.0% of LMP1 or LMP2-positive CD8^+^ T cells in cocultures with pLMP1/2-transfected DCs, and a background level of LMP1 or LMP2- positive CD8^+^ T cells in coculture with Mock DCs ([Fig. 3A](#F3){ref-type="fig"}). Additionally, ICS assay showed that pshA20-LMP1/2 DCs substantially improved LMP-specific CD8^+^ CTL responses, for after coculture with pshA20-LMP1/2 DCs, 10.95% of CD8^+^ T cells turned to IFN-γ-positive and 22.25% of CD8^+^ T cells TNF-α-positive, whereas coculture with pLMP1/2 DCs only rendered 1.88 % of CD8^+^ T cells IFN-γ-positive and 5.71% of CD8^+^ T cells to express TNF-α. Mock DCs activated the cocultured CD8^+^ T cells to express IFN-γ (0.93%) or TNF-α (1.23%) with much lower efficiency ([Fig. 3B](#F3){ref-type="fig"}). ELISPOT assays further supported that an increased frequency of T cells from coculture with pshA20-LMP1/2 DCs produced IFN-γ in response to re-stimulation of LMP1 MHC-I peptide, LMP2 MHC-I peptide, or a mixture of these peptides compared with those from coculture with pLMP1/2 DCs or Mock DCs ([Fig. 3C](#F3){ref-type="fig"}). In comparison to tetramer analyses, IFN-γ ELISPOT assays seem to underestimate the frequency of epitope-specific T cells. The reason may partially be owed to that only a certain percentage of tetramer-positive T cells secrete IFN-γ after specific stimuation^[@R30]--[@R31]^. Furthermore, a low concentration of LMP peptides were used for pulsing autologous DCs for in vitro restimulation, which may also contribute to the low frequency of epitope-specific T cells detected in these ELISPOT assays. ELISPOT analysis of LMP-specific CTL activation from different HLA-A2^+^ healthy buffy coats was summarized in [Table 1](#T1){ref-type="table"}.

We next determined whether activated T cells possess tumor lytic function by using LMP peptide-pulsed tumor cells or EBV-transformed, autologous B-lymphoblastoid cell lines (LCLs) as target cells for CTL assays. As shown in [Fig. 4A](#F4){ref-type="fig"}, while T cells activated by Mock DCs barely showed any cytolytic activity to LMP1/LMP2-pulsed, HLA-A2^+^ lymphoblastoma cell line T2 or EBV-transformed LCLs, and T cells activated by pLMP1/2 DCs exhibited low cytolytic activities to these tumor target cells, T cells from the coculture with pshA20-LMP1/2 DCs displayed strong CTL activities against either LMP1/2 peptide-pulsed T2 lymphoblastoma cells or EBV-transformed, HLA-A2 restricted LCL. The tumor cytolytic activity was LMP antigen-specific, as the activated lymphocytes by pshA20-LMP1/2 DCs or pLMP1/2 DCs only had a background cytolytic activity against Mage3-pulsed T2 or HLA-A2^+^ renal carcinoma A498 cells (data not shown). It has been known that pretreatment with anti-inflammatory cytokine IL-10 promotes tolerogenic function of hDCs^[@R32]^. We further tested whether incubation of pshA2-LMP1/2 DCs with 10 ng/ml of IL-10 could ablate its superior immunostimulatory activity. We found that although pretreatment with IL-10 reduced either pshA20-LMP1/2 DCs or pLMP1/2 DCs to activate CTL response against LMP1/LMP2-pulsed T2 cells, T cells primed by IL-10-treated pshA20-LMP1/2 DCs still displayed higher cytotoxicity against the tumor cell line compared with those activated by IL-10-treated pLMP1/2 DCs ([Fig. 4B](#F4){ref-type="fig"}). Repeated experiments from different donors showed similar results. Collectively, these results indicate that pshA20-LMP1/2 DCs have enhanced immunostimulatory ability to prime EBV subdominant antigen-specific CTLs.

pshA20-LMP1/2 transfection enhances hDCs to prime type-I CD4^+^ T cell response *in vitro* {#S6}
------------------------------------------------------------------------------------------

To further explore the mechanism by which A20-silenced hDCs provoke more potent CTL responses against LMP, we compared the CD4^+^ T cell response in the cocultures with different DCs, given the importance of CD4^+^ T cells in coordinating immune responses by production of various cytokines. We found that after coculture with pshA20-LMP1/2 DCs, 16.12% or 23.58% of CD4^+^ T cells produced IFN-γ or TNF-α compared with only 3.09% or 6.22% of CD4^+^ T cells that express IFN-γ or TNF-α after coculture with pLMP1/2 DCs, and compared with the background levels of CD4^+^ T cells (0.87% or 0.56%) that express the cytokines after coculture with Mock DCs ([Fig. 5A](#F5){ref-type="fig"}). In contrast, pshA20-LMP1/2 DC does not show any advantage over pLMP1/2 DC in promoting expression of type-II cytokines by cocultured CD4^+^ T cells (data not shown). These results are consistent with our previously published studies that A20-silenced DCs or macrophages preferentially prime IFN-γ/TNF-α-producing T cells and provoke a type-I immune environment^[@R6],\ [@R33]^. More intriguingly, A20-silenced hDCs via siRNA oligo, when pulsed or treated with Hodgkin lymphoma HDLM2 tumor lysate (TL), display a large reduction in eliciting IL-10 expression by cocultured CD4^+^ T cells compared with control siRNA-transfected, TL-treated hDCs, as shown by ELISA analysis of IL-10 moiety in the supernatants of the primed CD4^+^ T cell cultures ([Fig. 5B](#F5){ref-type="fig"}, **left**) or by ICS analysis of the cocultured CD4^+^ T cells ([Fig. 5B](#F5){ref-type="fig"}, **right**). Furthermore, we tested immunosuppressive activity of these different DC-primed CD4^+^ T cells by coculturing the primed CD4^+^ T cells with naïve autologous CD4^+^ T cells at different ratios in the presence of anti-CD3 as described. ^3^H-Thymidine incorporation assay explored that the CD4^+^ T cells primed by A20-silenced, TL-treated DCs showed a reduced ability to inhibit naïve autologous CD4^+^ T cell proliferation ([Fig. 5C](#F5){ref-type="fig"}). Hodgkin lymphoma patients are characterized by profound systemic immunosuppression^[@R34]^. Hodgkin lymphoma cells secrete high levels of IL-10 and TGF- β^[@R35]^, as confirmed by ELISA analysis of HDLM2 supernatants ([Supplementary Fig. 3](#SD2){ref-type="supplementary-material"}), to inhibit activation of type-I immune responses, versus to promote type-II or regulatory T cell responses^[@R36]^. These results may implicate that A20-silenced DCs not only promote type-I immunity, also have enhanced refraction to tumor-mediated differentiation of tolerogenic function.

As shown in [Fig. 2B](#F2){ref-type="fig"}, pshA20-LMP1/2-transfected DCs not only produce higher levels of proinflammatory cytokines, they also produce an elevated amount of anti-inflammatory cytokine IL-10. Hence, we did down-regulation of IL-10 or its signaling in hDCs by IL-10 siRNA or IL-10 receptor (IL-10R) siRNA oligos. We found that down-regulation of IL-10 or its signaling by the siRNAs does not significantly impact DC expression of IL-12 ([Supplementary Fig. 4A](#SD2){ref-type="supplementary-material"}), a key cytokine in the activation of CTL responses^[@R37]^, which is consistent with the previously reported results from Breckpot et al.^[@R38]^. However, downregulation of IL-10 or IL-10R with siRNA significantly enhanced IL-12 expression in TL-treated hDCs ([Supplementary Fig. 4A](#SD2){ref-type="supplementary-material"}), which is coherent with an earlier study that autocrine production of IL-10 mediates defective IL-12 production in tumor-associated macrophages^[@R39]^. We further found that down-regulation of IL-10 also reduced TL-pulsed hDC to induce IL-10-expressed CD4^+^ T cells albeit with a lesser extent than down-regulation of A20 alone ([Supplementary Fig. 4B](#SD2){ref-type="supplementary-material"}).

pshA20-LMP1/2 DC-activated T cells have improved control of tumor growth *in vivo* {#S7}
----------------------------------------------------------------------------------

To assess whether pshA20-LMP1/2 DC-activated T cells could effectively control the growth of EBV^+^ lymphomas *in vivo*, we used a SCID mouse xenograft model. 5 to 6 week-old sublethally irradiated SCID mice (6 mice per group) were implanted with FFLuc-labeled EBV^+^ lymphomas in the peritoneal cavity and monitored for tumor growth by examining light emission of implanted tumor cells. Once tumor bioluminescence in the tumor-inoculated mice was found progressively increasing, which usually occurred at day 4--5 after tumor injection, mice were treated intraperitoneally with *in vitro* primed autologous T cells (1×10^7^) by differently transfected DCs or Mock DCs at days 5 and 12 post tumor cell inoculation. Based on 22% of CD8^+^ T cells present 2 -- 3 weeks after coculture ([Supplemental Fig. 5](#SD2){ref-type="supplementary-material"}) and 5.22% or 22.5% of the CD8^+^ T cells LMP1 or LMP2-positive ([Fig. 3A](#F3){ref-type="fig"}), in the pshA20-LMP1/2 DC group, a \~5.0×10^5^ of LMP2^+^ and \~1.2×10^5^ of LMP1^+^ CD8^+^ T cells were used for adaptive transfer each time. As shown in [Fig. 6A & B](#F6){ref-type="fig"}, the mice treated with Mock DC-primed T cells exhibited progressively increased tumor bioluminescence and the mice treated with pLMP1/2 DC-primed T cells displayed slightly decreased tumor bioluminescence, whereas the mice treated with pshA20-LMP1/2 DC-primed T cells had dramatically reduced tumor bioluminescence during the observed period and some of them achieved nearly complete extinguishment of tumor bioluminescence by day 28 after tumor implantation. Accordingly, treatment of pshA20-LMP1/2 DC-primed T cells also contributed to an improved survival compared with mice receiving pLMP1/2 DC- or Mock DC-primed T cells. [Fig. 6C](#F6){ref-type="fig"} showed that all the mice treated with pshA20-LMP1/2 DC-primed T cells survived during the observed period (more than 50 days after tumor injection). Hence, pshA20-LMP1/2 DC-primed T cells can control tumor growth *in vivo* with a higher efficiency.

Discussion {#S8}
==========

Adoptive transfer of EBV-specific CTLs is extremely effective in treating EBV-associated malignant lymphomas caused by hemopoietic stem cell transplantation in highly immunosuppressed patients^[@R13]--[@R14],\ [@R40]^. The reason is attributed to these lymphoma cells expressing all of the latent EBV proteins including the immunodominant EBV nuclear Ag (EBNA) 3 proteins, which are targeted by a majority of EBV-CTL populations. However, EBV infection leads to HD in some immunocompetent hosts and the malignant Reed-Sternberg cells of HD develop a multiplicity of immune evasion mechanisms, including the down-regulation of the immunodominant EBV nuclear antigens, to evade preexisting immune responses to EBV. Nevertheless, the tumor cells continue to express the immunologically subdominant viral latency proteins such as LMP1 and LMP2. To generate CTLs against the LMP antigen for the adoptive immunotherapy of EBV-associated malignancies, Gahn et al. found that human monocyte-derived DCs transduced by recombinant adenoviruses encoding LMP2A effectively directed the generation of LMP2A-specific CTLs with much higher efficiency than autologous LCLs. Considering that only small amounts of patient peripheral blood can be collected to produce LMP-expressing DCs, Bollard et al. devised an initial activation of LMP2-specific CTLs by LMP2-transfected DCs followed by stimulation with LCLs overexpressing LMP2 to produce large numbers of LMP2-specfic CTLs, which are demonstrated to contain both CD4^+^ and CD8^+^ T cells and recognize multiple LMP2-epitopes^[@R23]^. Furthermore, Bollard et al. used these *in vitro* activated autologous and donor-derived CTL lines to treat a patient with multiple relapsed EBV positive HD after multiple chemotherapeutic and radiotherapy regimens and rendered the treated patient to remain in complete remission 5 years post-allogenic stem cell transplantation^[@R15]^. The same group also observed that *in vitro* activated, LMP2-specific CTLs could expand and persist for a long time after transfer into patients and had substantial antitumor activity in the patient recipients^[@R41]^. As another potential target for HD immunotherapy, the full-length LMP1 is toxic when expressed at high levels, which has prevented DCs from being used for CTL stimulation. Gottschalk et al. therefore defined that an inactive, non toxic LMP1 mutant (ΔLMP1) could be expressed in DCs via an adenoviral vector, and the ΔLMP1-expressed DCs enabled the activation and expansion of polyclonal LMP1-specific CTLs^[@R26]^. Collectively, these studies highlighted that LMP-specific CTLs can be generated *in vitro* and both autologous and donor-derived CTLs can be used for adoptive immunotherapy to combat against EBV-associated malignancies to a certain extent.

Given the fact that DCs are equipped with multiple negative regulatory mechanisms in the maintenance of self-tolerance^[@R42]^, we coexpressed a shRNA of A20, a key negative regulator of proinflammatory signaling pathways, together with LMP1/LMP2 to promote the ability of hDCs to activate LMP-specific CTLs. We found that pshA20-LMP1/2-transfected DCs exhibit more mature phenotypes and produced higher levels of inflammatory cytokines in response to stimulation of a TLR-ligand. As a consequence, the pshA20-LMP1/2-transfected DCs primed more potent CTL responses, as manifested by higher frequencies of CD8^+^ T cells LMP tetramer-positive, and large percentages of CD8^+^ T cells to express IFN-γ or TNF-α. Furthermore, the CTLs activated by pshA20-LMP1/2-transfected DCs exhibited stronger cytotoxicity against EBV^+^ tumor cells, and functioned more efficiently in controlling EBV-transformed tumors after adoptive transfer into SCID mice. These results suggested that silencing the negative regulator A20 can boost the ability of hDCs to prime the LMP-specific CTL response. The experimental results are also consistent with our previously reported studies in which A20-silenced murine DCs displayed a superior immunostimulatory function.^[@R6],\ [@R28]^.

Overall, the study demonstrated that transient expression of an A20 inhibitor enhanced the efficiency of LMP-expressing hDCs to prime the LMP-specific CTL response. The finding potentially provides an approach which allows small numbers of patient DCs to operate as APCs for activation of LMP-specific CTLs more efficiently. This strategy is also likely to benefit for generation of other tumor-specific CTLs for adoptive immunotherapy, especially when weak tumor antigens are targeted

Materials and Methods {#S9}
=====================

Construction of expression vectors {#S10}
----------------------------------

The control vector pLMP1/2 expresses the truncated EBV LMP1 (ΔLMP1) and a full-length LMP2 with an IRES (internal ribosome entry site) link under the control of CMV promoter. To construct the co-expression vector pshA20-LMP1/2, which additionally expresses a small hairpin shRNA of human A20 (shA20) under the control of the U6 promoter, synthetic shA20 oligo duplex (5′-GATCCCCCCCATGCACCGATACACACTTTCAAGAGAAGTGTGTATCGGTGCATGGTTTTTGGAAA-3') was cloned into pSilencer2.0-U6 (Ambion). The U6 RNA polymerase promoter-shA20 fragment was generated by PCR and cloned into the Spe-I-digested plasmid pLMP1/2. The sequences of the inserts in the plasmid were confirmed by DNA sequencing (Lone Star Labs, Inc, Houston, TX).

Generation and transfection of human monocyte-derived DCs {#S11}
---------------------------------------------------------

Human monocyte-derived DCs were prepared from peripheral blood mononuclear cells (PBMCs) of buffy coat (Gulf Coast Regional Blood Center, Houston, TX) as described in our previous studies^[@R43]--[@R45]^. For hDC transfection, the monocyte-derived DCs were harvested for nucleofection with different siRNAs or expression vectors according to the manufacturer's instruction (Amaxa Inc., Gaithersburg, MD) for further studies.

Quantitative PCR (q-PCR) assay {#S12}
------------------------------

For qPCR analyses of the nucleofected DCs, the qPCR primers were synthesized as below: human A20 primers (5'-CACGCTCAAGGAAACAGACA-3'; 5'-CATGGGTGTGTCTGTGGAAG-3'); LMP1 primers (5'-TGAACACCACCACGATGACT-3'; 5'-GTGCGCCTAGGTTTTGAGAG-3'); LMP2 primers (5'-TCCATCTGCTTCTGGCTCTT-3'; 5'-ATGAGTCATCCCGTGGAGAG-3').

Tetramer and intracellular staining (ICS) {#S13}
-----------------------------------------

For tetramer staining, an HLA-A2-restricted EBV LMP1 peptide (YLQQNWWTL)^[@R26],\ [@R46]^, an HLA-2-restricted LMP2 peptide (CLGGLLTMV)^[@R23]^, and a control human melanoma antigen MAGE3 peptide (FLWGPRALV) were synthesized and purified by HPLC to \>95% purity by Genemed Synthesis Inc. (South San Francisco, CA, USA)^[@R47]^. Human LMP1/HLA-A2 tetramer and human LMP2/HLA-A2 tetramer were synthesized at the Baylor College of Medicine Tetramer Core Facility (Houston, TX, USA). For ICS assay, the co-cultured T cells were re-stimulated for six hours in the presence of the protein transport inhibitor GolgiPlug (BD Biosciences, Erembodgem, Belgium). After cell surface staining, cells were permeabilized with BD perm/wash solution, and then stained with specific monoclonal antibodies (BD Bioscience).

ELISA and ELISPOT assay {#S14}
-----------------------

Levels of various proinflammatory cytokines were quantified from the supernatant of DC or T cell cultures by ELISA analysis (BD Biosciences) according to the manufacturer's instructions. ELISPOT assays were performed as described previously^[@R6],\ [@R43]^. Briefly, MultiScreen-HA plates (Millipore, Bedford, MA) were incubated with the anti-human IFN-γ mAb 1-D1K (Mabtech, Stockholm,Sweden) overnight, and then blocked with RPMI 1640 supplemented with 10% human serum (Bethyl, Inc., Montgomery, TX). Primed T cells (1×10^5^) were co-cultured with irradiated peptide-pulsed autologous DCs (4×10^3^) in the coated plate for 20 hr at 37°C. After washing, biotinylated anti-human IFN-γ antibody 7-B6-1 (Mabtech) was added to the wells, and then incubated for 2 hr. After another wash, HRP-conjugated avidin was added to the wells and incubated for 1 hr. Finally, spots were developed by the addition of HRP substrate (Vectastain ABC Kit, Vector Laboratories). After spot development, the plate was rinsed thoroughly with ddH~2~O and allowed to dry. Spots were analyzed by Zellnet Consulting, Inc. (New York).

Priming of autologous T cells {#S15}
-----------------------------

*In vitro* priming of autologous T cells was performed as reported^[@R43]--[@R44]^. 1×10^5^ human DCs nucleofected with either pshA20-LMP1/2, pLMP1/2, or PBS were harvested and then co-cultured with autologous lymphocytes at a ratio of 1:20 in the presence of recombinant human IL-2 (50 U/ml) (R&D Systems). The T cells were re-stimulated weekly with freshly prepared nucleofected DCs. After 2--3 weeks of co-culture, the lymphocytes were collected for immunological assays.

CTL assay {#S16}
---------

CD8^+^ CTL responses were assessed with LDH release assay (Roche Diagnostics). Briefly, DC-primed T cells were re-stimulated with 20 µg/ml LMP1 and 20 µg/ml LMP2 peptide-pulsed autologous DCs for two hours. LMP1, LMP2, or Mage3-pulsed T2 or A498, or autologous LCL served as target cells. 10^4^ target cells and various numbers of DC-primed T cells were cocultured at 37°C in 96-well round-bottom plates. Four hours later, 100 µl of the supernatant was harvested from each well, mixed with LDH reagents, and analyzed by absorbance at OD~490~ in the Microwin 2000 counter. The percent lysis was defined as (experimental LDH release - spontaneous LDH release)/(maximal LDH release - spontaneous LDH release) × 100%. Spontaneous and maximal LDH releases were determined in the presence of either medium or 2% Triton-100, respectively.

Antitumor activity {#S17}
------------------

To evaluate *in vivo* antitumor activity, autologous EBV^+^-LCLs were generated by transforming PBMC with EBV B95-8 virus (ATCC) and expanded for 3--4 weeks. EBV^+^-LCLs were transfected with FFLuc vector and selected using 2 µg/ml puromycin (Invitrogen) for 1--2 weeks. C57/SCID mice (5 to 6 weeks-old, Jackson Laboratories) were sublethally irradiated (230 cGy) and xenografted intraperitoneally with 3×10^6^ FFLuc^+^ EBV^+^-LCLs resuspended in Matrigel (BD Biosciences)^[@R48]--[@R49]^. CTLs (10×10^6^ per mouse) activated by pshA20-LMP1/2, control pLMP1/2, or Mock DC were injected intraperitoneally at day 5 and 12 after intraperitoneal tumor implantation (6 mice per group). Tumor growth was evaluated over time using the IVIS imaging system. A constant region of interest was drawn over the tumor regions and the intensity of the signal measured as total photon/sec/cm^2^/steradian (p/s/cm^2^/sr) as previously described^[@R49]--[@R50]^.

Statistical analysis {#S18}
--------------------

For statistical analysis, we used Student\'s t test or Chi-square test (indicated when being used), and a 95% confidence limit was taken to be significant, defined as *p* \< 0.05. Results are typically presented as means ± standard errors (SE).
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![The construction and characterization of pshA20-LMP1/2\
**A.** schematic representation of pshA20-LMP1/2 and control vector pLMP1/2. **B.** monocyte-derived DCs were nucleofected on day five with different vectors and matured with LPS (100 ng/ml) overnight. LMP1 and LMP2 expression in the DCs were analyzed 24 hours after nucleofection by western blot analysis. The antibody against EBV LMP1 or LMP2 was purchased from Santa Cruz Biotech (San Diego, CA). **C.** LMP1 and LMP2 mRNA levels were analyzed by qPCR 12hr after nucleofection. **D.** A20 mRNA level was analyzed by qPCR and data were normalized with mock DC A20 mRNA 24hr after nucleofection (upper). A20 protein expression was analyzed by western blot 24 hrs after nucleofection (lower). The data are representative of two independent experiments. \**P* \< 0.01, pshA20-LMP1/2/LPS DCs *vs*. Mock/LPS DCs.](nihms324802f1){#F1}

![pshA20-LMP1/2-nucleofected hDCs exhibit more mature phenotypes\
Monocyte-derived DCs were nucleofected with pshA20-LMP1/2 or pLMP1/2 on day 5 then stimulated with LPS o.n. Expression of costimulatory and MHC molecules was analyzed by flow cytometry **(A).** The culture media were harvested for analysis of cytokine production by ELISA **(B)**. The data are representative of three independent experiments. \**P* \< 0.01, pLMP1/2 DCs vs. pshA20-LMP1/2 DCs.](nihms324802f2){#F2}

![pshA20-LMP1/2-nucleofected DCs have an enhanced ability to prime or activate LMP1/2-specific effector T cell responses\
Autologous HLA-A2^+^ lymphocytes were co-cultured with the nucleofected DCs for 2--3 weeks with weekly re-stimulation. Priming of CD8^+^ T cells were assessed by LMP1- or LMP2-tetramer staining **(A)**, ICS assay **(B)**, and IFN-γ ELISPOT **(C)**. The data are representative of the analyzed 5 buffy coats. \**P* \< 0.05, pshA20-LMP1/2 DCs *vs*. pLMP1/2 DCs.](nihms324802f3){#F3}

![pshA20-LMP1/2-nucleofected DCs have an enhanced ability to stimulate CTL activity\
**A.** Autologous HLA-A2^+^ T cells were cocultured with differently treated DCs for two weeks. CTL activities against T2 cell line pulsed with 20 µg/ml of LMP1/LMP2 peptides (left), autologous HLA-A2^+^EBV^+^LCL (middle) or T2 cell line pulsed with 20 µg/ml MAGE3 (right) were evaluated by LDH assay. The data are representative of two analyzed buffy coats. *P* \< 0.05 (chi-square), pshA20-LMP1/2 DCs *vs*. pLMP1/2 DC-primed T cells. **B.** The autologous HLA-A2^+^ T cells were co-cultured with different DCs in the absence or presence of pretreatment with IL-10 for two weeks with weekly re-stimulation. CTL activities against LMP1/2-pulsed T2 cell line or CTL activity against MAGE3- pulsed T2 cells was evaluated by LDH assay. The data are representative of two analyzed buffy coats. *P* \< 0.05 (Chi-square), pshA20-LMP1/2 DCs *vs*. pLMP1/2 DC-primed T cells.](nihms324802f4){#F4}

![Priming of CD4^+^ T cells by differently transfected or Mock DCs\
**A.** Autologous T cells were cocultured with pshA20-LMP1/2-DCs, pLMP1/2-DCs, or Mock DCs for two weeks. Priming of CD4^+^ T cells were assessed by ICS assay. **B.** hDCs were transfected with A20 siRNA (siA20) or mutant A20 siRNA (siMut) and pulsed with HDLM2 tumor lysates (5:1) for 48 hrs. After 6 hr of LPS stimulation, the hDCs were cocultured with autologous CD4^+^ T cells for 7--9 days. IL-10 expression in the cocultured CD4^+^ T cells was determined by ELISA (**left**) and ICS (**right**). **C.** The primed CD4^+^ T cells by TL-pulsed, siRNA-transfected DCs were cocultured with naïve autologous CD4^+^ T cells (CD4^+^CD45RA^+^) at varying ratios in anti-CD3-coated 96 well plates. T cell proliferation was determined by ^3^H-Thymidine incorporation assay. \*p \< 0.05, siA20/TL vs. siMut/TL.](nihms324802f5){#F5}

![CTLs primed by pshA20-LMP1/2 exhibit enhanced anti-tumor immunity\
T cells primed by different DCs were injected intraperitoneally into SCID mice bearing EBV^+^ lymphoma labeled with FFLuc at day 5 and 12 after intraperitoneal tumor implantation. Tumor growth was measured weekly as maximum p/s/cm^2^/sr. Lines represent the average light emission ± SD (**A**). Pictures of 3 representative mice per group at day 7 and day 28 (**B**). The survival curve for SCID mice bearing EBV^+^ lymphoma that received CTLs primed by differently transfected or Mock DCs (**C**).](nihms324802f6){#F6}

###### 

IFN-γ ELISPOT analysis of CTL priming from different HLA A2 buffy coats

  Peptide         MAGE3        LMP1         LMP2         LMP1+LMP2
  --------------- ------------ ------------ ------------ ------------
  **Donor A**                                            
  Mock            15 ± 1.6     36 ± 3.1     41 ± 3.2     72 ± 6
  pLMP1/2         23 ± 2       142 ± 8      156 ± 6      298 ± 11
  pshA20-LMP1/2   36 ± 1.2     265.3 ± 14   322 ± 12     549 ± 25
  **Donor B**                                            
  Mock            8 ± 0.3      12 ± 1       34 ± 4       76 ± 5
  pLMP1/2         10 ± 1       25 ± 1.2     72.3 ± 2.5   128 ± 15
  pshA20-LMP1/2   13.3 ± 0.6   88 ± 5       103 ± 8      195 ± 4.5
  **Donor C**                                            
  Mock            52 ± 4       73 ± 2.5     60 ± 2.1     82 ± 8.3
  pLMP1/2         42 ± 7       181 ± 16     269 ± 15     486 ± 12.5
  pshA20-LMP1/2   48 ± 6.3     276 ± 10     526 ± 22     729 ± 18
  **Donor D**                                            
  Mock            28 ± 1.4     34 ± 4       63 ± 8       72 ± 0.5
  pLMP1/2         21 ± 3       73.3 ± 2.2   158 ± 3      194 ± 6
  pshA20-LMP1/2   17 ± 0.5     126 ± 7      203 ± 13.3   362 ±14
  **Donor E**                                            
  Mock            6.6 ± 1.3    16 ± 3       29 ± 1.3     45 ± 3
  pLMP1/2         4 ± 2        38 ± 5       89 ± 7       102 ± 6
  pshA20-LMP1/2   17 ± 4       71 ± 1.2     176 ± 6      284 ± 8

Numbers are mean ± SD of interferon γ (IFNγ) spot-forming cells/10^5^ autologous T cells cocultured with different DCs.
